Boys Arnold & Co. Inc. cut its position in shares of Aetna Inc. (NYSE:AET) by 1.6% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 39,730 shares of the company’s stock after selling 656 shares during the period. Aetna accounts for approximately 0.8% of Boys Arnold & Co. Inc.’s portfolio, making the stock its 27th largest position. Boys Arnold & Co. Inc.’s holdings in Aetna were worth $6,032,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Guardian Life Insurance Co. of America boosted its stake in Aetna by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,353 shares of the company’s stock worth $173,000 after buying an additional 9 shares in the last quarter. Concert Wealth Management Inc. boosted its stake in Aetna by 0.4% in the first quarter. Concert Wealth Management Inc. now owns 3,262 shares of the company’s stock worth $405,000 after buying an additional 14 shares in the last quarter. Rehmann Capital Advisory Group raised its position in shares of Aetna by 1.1% in the first quarter. Rehmann Capital Advisory Group now owns 2,335 shares of the company’s stock valued at $298,000 after buying an additional 25 shares during the last quarter. Geneva Advisors LLC raised its position in shares of Aetna by 1.0% in the first quarter. Geneva Advisors LLC now owns 2,588 shares of the company’s stock valued at $330,000 after buying an additional 25 shares during the last quarter. Finally, JNBA Financial Advisors raised its position in shares of Aetna by 0.7% in the first quarter. JNBA Financial Advisors now owns 3,726 shares of the company’s stock valued at $475,000 after buying an additional 27 shares during the last quarter. Institutional investors own 91.69% of the company’s stock.

Shares of Aetna Inc. (NYSE:AET) traded down 0.03% during midday trading on Friday, reaching $156.10. The company’s stock had a trading volume of 1,041,699 shares. The stock has a 50 day moving average of $155.24 and a 200-day moving average of $141.63. Aetna Inc. has a 1-year low of $104.59 and a 1-year high of $161.69. The company has a market capitalization of $51.84 billion, a P/E ratio of 34.65 and a beta of 0.54.

Aetna (NYSE:AET) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.34 by $1.08. Aetna had a net margin of 2.52% and a return on equity of 20.52%. The firm had revenue of $15.52 billion during the quarter, compared to the consensus estimate of $15.34 billion. During the same period last year, the firm posted $2.21 EPS. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. On average, equities research analysts anticipate that Aetna Inc. will post $9.55 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/26/boys-arnold-co-inc-has-6-03-million-position-in-aetna-inc-aet.html.

Several brokerages have issued reports on AET. UBS AG reaffirmed a “buy” rating and set a $160.00 price objective (up previously from $147.00) on shares of Aetna in a report on Wednesday, May 17th. Argus reaffirmed a “buy” rating and set a $165.00 price objective (up previously from $145.00) on shares of Aetna in a report on Tuesday, May 30th. Morgan Stanley raised their price objective on Aetna from $172.00 to $179.00 and gave the stock an “overweight” rating in a report on Thursday, August 17th. Credit Suisse Group reaffirmed a “buy” rating and set a $155.00 price objective on shares of Aetna in a report on Wednesday, May 17th. Finally, Cleveland Research raised Aetna from a “neutral” rating to a “buy” rating in a report on Thursday, May 11th. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $157.99.

In related news, EVP Margaret M. Mccarthy sold 27,028 shares of Aetna stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $149.23, for a total transaction of $4,033,388.44. Following the completion of the transaction, the executive vice president now directly owns 33,563 shares of the company’s stock, valued at approximately $5,008,606.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.90% of the company’s stock.

About Aetna

Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.

Institutional Ownership by Quarter for Aetna (NYSE:AET)

Receive News & Stock Ratings for Aetna Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc. and related stocks with our FREE daily email newsletter.